Draft Guidance Reduces Safety Reporting for Some Drug Trials
Drug sponsors may be able to collect less and better-targeted safety data in late-stage or postmarket trials if certain aspects of the safety profile are already well established, according to a new draft guidance.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.